New use for an old drug: Metformin and atrial fibrillation
Letter 2022 en
Authors
MV
Manlio Vinciguerra
IO
Iván Olier
SO
Sandra Ortega‐Martorell
Abstract
1 min read
Lal and colleagues<sup>1</sup> reported an integrative approach-combining transcriptomics, iPSCs, and epidemiological evidence-to identify and repurpose metformin, a main first-line medication for the treatment of type 2 diabetes, as an effective risk reducer for atrial fibrillation.
Tengteng Wang, Jae H. Kang, Boyang Chai, Wendy Y. Chen, Michelle D. Holmes, Jennifer Erdrich, Edward L. Giovannucci, Frank B Hu, Bernard Rosner, Rulla M. Tamimi, Walter C. Willett, A. Heather Eliassen
Mia Vicki Fangel, Peter Brønnum Nielsen, Torben Bjerregaard Larsen, Bo Christensen, Thure Filskov Overvad, Professor Gregory Lip, Samuel Z. Goldhaber, Martin Bach Jensen
Discussion(0)
No comments yet. Be the first to comment.